Literature DB >> 16845886

Cytochrome p450 2C (CYP2C) in ischemic heart injury and vascular dysfunction.

Manreet K Chehal1, David J Granville.   

Abstract

The cytochrome p450 2C (CYP2C) monooxygenase family is a key player in the generation of epoxyeicosatrienoic acids. It has recently become apparent that CYP plays an important role in cardiovascular physiology and contributes to the pathogenesis of various cardiovascular diseases. In particular, several studies have demonstrated a role for these enzymes in cardiac ischemia and reperfusion injury. The current review summarizes the role of the CYP epoxygenase, CYP2C9, in ischemic heart disease and vascular homeostasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16845886     DOI: 10.1139/y05-139

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  6 in total

Review 1.  Ischemia/Reperfusion.

Authors:  Theodore Kalogeris; Christopher P Baines; Maike Krenz; Ronald J Korthuis
Journal:  Compr Physiol       Date:  2016-12-06       Impact factor: 9.090

Review 2.  Cell biology of ischemia/reperfusion injury.

Authors:  Theodore Kalogeris; Christopher P Baines; Maike Krenz; Ronald J Korthuis
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

Review 3.  The transcriptional regulation of the human CYP2C genes.

Authors:  Yuping Chen; Joyce A Goldstein
Journal:  Curr Drug Metab       Date:  2009-07-15       Impact factor: 3.731

4.  Endosomal NADPH oxidase regulates c-Src activation following hypoxia/reoxygenation injury.

Authors:  Qiang Li; Yulong Zhang; Jennifer J Marden; Botond Banfi; John F Engelhardt
Journal:  Biochem J       Date:  2008-05-01       Impact factor: 3.857

5.  Sulfaphenazole reduces thermal and pressure injury severity through rapid restoration of tissue perfusion.

Authors:  Christopher T Turner; Megan Pawluk; Juliana Bolsoni; Matthew R Zeglinski; Yue Shen; Hongyan Zhao; Tatjana Ponomarev; Katlyn C Richardson; Christopher R West; Anthony Papp; David J Granville
Journal:  Sci Rep       Date:  2022-07-23       Impact factor: 4.996

6.  Pharmacogenetics of rheumatoid arthritis: Potential targets from susceptibility genes and present therapies.

Authors:  Darren D O'Rielly; Proton Rahman
Journal:  Pharmgenomics Pers Med       Date:  2010-03-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.